Evidence map›Paper›PMID 35963365›Full record

ArticleGastroenterology2022

Durability of Immunity Is Low Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1, BA.2, and BA.3 Variants After Second and Third Vaccinations in Children and Young Adults With Inflammatory Bowel Disease Receiving Biologics.

Lorenza Bellusci, Fatema Tuz Zahra, Dena E Hopkins, Juan C Salazar, Jeffrey S Hyams, Surender Khurana

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lorenza BellusciDivision of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Fatema Tuz ZahraDivision of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Dena E HopkinsDepartment of Pediatrics, Connecticut Children's Medical Center, Hartford, Connecticut; School of Medicine, University of Connecticut, Farmington, Connecticut.
Juan C SalazarDepartment of Pediatrics, Connecticut Children's Medical Center, Hartford, Connecticut; School of Medicine, University of Connecticut, Farmington, Connecticut.
Jeffrey S HyamsDepartment of Pediatrics, Connecticut Children's Medical Center, Hartford, Connecticut; School of Medicine, University of Connecticut, Farmington, Connecticut.
Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. Electronic address: Surender.Khurana@fda.hhs.gov.
Center for Biologics Evaluation and Research · USConnecticut Children's Medical Center · US

Funding

Identifying biomarker signatures of prognostic value for Multisystem Inflammatory Syndrome in Children (MIS-C)R61HD105613 · NICHD · CONNECTICUT CHILDREN'S MEDICAL CENTER · PI LAWRENCE, DAVID A, LYNES, MICHAEL A · 2021 to 2022
$1.9M
NICHD NIH HHS R61 HD105613
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biological ProductsCOVID-19Inflammatory Bowel DiseasesChildChronic DiseaseHumansSARS-CoV-2VaccinationYoung AdultBiological Products

Identifiers

PMID35963365
PMCPMC9364917
OpenAlexW4291397329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.